IDegLira is a fixed-ratio combination of degludec and liraglutide indicated for the treatment of type 2 diabetes (T2D). This is the first real world study describing change in glycated hemoglobin (HbA1c) among U.S. patients initiating IDegLira. The primary objective was to observe the effect in metabolic control of initiating IDegLira in adult T2D patients previously on basal insulin (Basal), glucagon-like peptide-1 receptor agonist as only injectable (GLP-1), and no injectable therapy (N-INJ) between March 2017 and June 2018 (index date). Patients with HbA1c data 6 months prior to and 6m post index date were included from the Practice Fusion Electronic Health Record database. Of the 1,384 IDegLira patients, 206 patients had baseline, and follow-up HbA1c (180 ± 45 days) data. Changes in clinical outcomes were evaluated by paired t-test. Overall there was significant change in HbA1c of -0.9% (p<.001), and there was an HbA1c reduction in all three background therapy groups, ranging from -0.7 in the Basal to -1.0 in N-INJ (p<0.001). There was no significant change in weight in the overall group despite initiating or intensifying insulin therapy with IDegLira, as expected weight in the GLP-1 subgroup increased (3.0 lb; p<.05). Consistent with previous real-world studies, IDegLira is effective at lowering HbA1c across different background therapies with minimal impact on weight.


L.E. Egede: Consultant; Self; Novo Nordisk Inc. Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases. A. Bogdanov: None. L. Fischer: None. J. da Rocha Fernandes: Employee; Self; Novo Nordisk A/S. L. Kallenbach: Employee; Self; Veradigm.


Novo Nordisk

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at